TEVA · Teva Pharmaceutical Industries Limited American Depositary Shares
View on chart this person other insiders at TEVA
Insiders & Stakes
| Amir Elstein Director | ▲ Buy | Option Exercise | 2,118,455 Shares held | 6/5/2026 | View profile |
| Kare Schultz President and CEO | ▲ Buy | Option Exercise | 1,542,471 Shares held | 11/1/2022 | View profile |
| Richard D. Francis President and CEO | ▼ Sell | Open Market | 1,177,529 Shares held | 6/5/2026 | View profile |
| Sol J. Barer Director | ▲ Buy | Option Exercise | 448,011 Shares held | 6/5/2026 | View profile |
| Dethlefs Sven EVP, North America Commercial | ▼ Sell | Open Market | 165,381 Shares held | 3/7/2023 | View profile |
| Drape Eric Executive VP Global Operations | ▲ Buy | Option Exercise | 145,915 Shares held | 3/5/2024 | View profile |
| Eric A. Hughes See "Remarks" | ▼ Sell | Open Market | 134,877 Shares held | 8/3/2026 | View profile |
| Gerald M. Lieberman Director | ▲ Buy | Option Exercise | 130,149 Shares held | 6/5/2026 | View profile |
| Rosemary A. Crane Director | ▲ Buy | Option Exercise | 127,739 Shares held | 6/5/2026 | View profile |
| Perry Nisen Director | ▲ Buy | Option Exercise | 119,807 Shares held | 6/5/2026 | View profile |
| Ronit Satchi-Fainaro Director | ▼ Sell | Open Market | 111,986 Shares held | 8/21/2026 | View profile |
| Bergwerk Dov Acting Chief Legal Officer | ▲ Buy | Option Exercise | 96,983 Shares held | 2/28/2024 | View profile |
| Mark Sabag EVP, International Markets | ▼ Sell | Open Market | 80,760 Shares held | 5/1/2026 | View profile |
| Janet S. Vergis Director | ▲ Buy | Option Exercise | 73,697 Shares held | 6/6/2025 | View profile |
| Tal Zvi Zaks Director | ▼ Sell | Open Market | 73,247 Shares held | 8/5/2026 | View profile |
| Eliyahu Sharon Kalif EVP, Chief Financial Officer | ▼ Sell | Open Market | 65,621 Shares held | 6/11/2026 | View profile |
| Halfon Jean Michel Director | ▲ Buy | Option Exercise | 63,707 Shares held | 6/14/2022 | View profile |
| Christine Fox EVP, Head of U.S. Commercial | ▼ Sell | Open Market | 63,647 Shares held | 4/30/2026 | View profile |
| Nechemia Jacob Peres Director | ▲ Buy | Option Exercise | 58,765 Shares held | 6/14/2022 | View profile |
| Richard Daniell Exec. VP, European Commercial | ▼ Sell | Open Market | 55,755 Shares held | 5/5/2026 | View profile |
| Shani Eli EVP,Global Marketing&Portfolio | ▲ Buy | Option Exercise | 54,228 Shares held | 3/5/2023 | View profile |
| Inbar Galia See "Remarks" | ▲ Buy | Option Exercise | 46,011 Shares held | 3/5/2023 | View profile |
| Evan Lippman EVP, Business Development | ▼ Sell | Open Market | 25,591 Shares held | 8/17/2026 | View profile |
| Shalev Varda | ▲ Buy | Option Exercise | 22,504 Shares held | 6/6/2025 | View profile |
| Chen Lichtenstein | ▲ Buy | Option Exercise | 19,296 Shares held | 6/5/2026 | View profile |
| Amir Weiss Chief Accounting Officer | ▼ Sell | Open Market | 13,071 Shares held | 8/21/2026 | View profile |
| McAvoy David R. EVP, Chief Legal Officer | ▲ Buy | Open Market | 13,027 Shares held | 9/5/2025 | View profile |
| Grant Angus EVP, Business Development | ▼ Sell | Open Market | 8,848 Shares held | 8/9/2024 | View profile |
| Savage Brian Interim Chief Legal Officer | ▼ Sell | Open Market | 8,500 Shares held | 9/18/2026 | View profile |
| Placid Jover See "Remarks" | ▼ Sell | Open Market | 6,774 Shares held | 8/3/2026 | View profile |
| Stark David Matthew Exec. VP Chief Legal Officer | ▼ Sell | Open Market | 2,974 Shares held | 3/7/2023 | View profile |
| Fridriksdottir Hafrun Executive VP, Global R&D | ▼ Sell | Open Market | 1,387 Shares held | 5/17/2022 | View profile |
| Roberto Mignone Director | ▼ Sell | Open Market | 0 Shares held | 9/18/2026 | View profile |
| Matthew Shields EVP, Global Operations | ▼ Sell | Open Market | 0 Shares held | 6/18/2026 | View profile |
| Conway Vikki L See "Remarks" | ▼ Sell | Open Market | 0 Shares held | 5/13/2024 | View profile |
Transaction History
| Savage Brian | ▲ Buy | Option Exercise | 4,503 | $156K | 9/18/2026 |
| Savage Brian | ▼ Sell | Open Market | 4,503 | $174K | 9/18/2026 |
| Savage Brian | ▼ Sell | Open Market | 2,525 | $99K | 9/18/2026 |
| Savage Brian | ▼ Sell | Open Market | 314 | $12K | 9/18/2026 |
| Roberto Mignone | ▼ Sell | Open Market | 367,600 | $14.4M | 9/18/2026 |
| Amir Weiss | ▼ Sell | Open Market | 6,945 | $261K | 8/21/2026 |
| Amir Weiss | ▲ Buy | Option Exercise | 2,500 | $49K | 8/21/2026 |
| Amir Weiss | ▼ Sell | Open Market | 2,500 | $94K | 8/21/2026 |
| Ronit Satchi-Fainaro | ▼ Sell | Open Market | 415 | $15K | 8/21/2026 |
| Evan Lippman | ▼ Sell | Open Market | 18,600 | $680K | 8/17/2026 |
| Tal Zvi Zaks | ▼ Sell | Open Market | 17 | $593 | 8/5/2026 |
| Placid Jover | ▲ Buy | Option Exercise | 12,827 | — | 8/3/2026 |
| Placid Jover | ▼ Sell | Open Market | 12,827 | $447K | 8/3/2026 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 52,744 | — | 8/3/2026 |
| Eric A. Hughes | ▼ Sell | Open Market | 25,578 | $892K | 8/3/2026 |
| Matthew Shields | ▼ Sell | Open Market | 9,989 | $322K | 6/18/2026 |
| Eliyahu Sharon Kalif | ▼ Sell | Open Market | 106,563 | $3.6M | 6/11/2026 |
| Sol J. Barer | ▲ Buy | Option Exercise | 21,739 | — | 6/5/2026 |
| Chen Lichtenstein | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Rosemary A. Crane | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Amir Elstein | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Gerald M. Lieberman | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Perry Nisen | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Ronit Satchi-Fainaro | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Tal Zvi Zaks | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Roberto Mignone | ▲ Buy | Option Exercise | 14,492 | — | 6/5/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 13,043 | — | 6/5/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 6,153 | $211K | 6/5/2026 |
| Matthew Shields | ▲ Buy | Option Exercise | 16,195 | — | 6/3/2026 |
| Matthew Shields | ▼ Sell | Open Market | 16,195 | $532K | 6/3/2026 |
| Evan Lippman | ▲ Buy | Option Exercise | 11,841 | — | 5/14/2026 |
| Eliyahu Sharon Kalif | ▼ Sell | Open Market | 153,251 | $5.5M | 5/14/2026 |
| Evan Lippman | ▼ Sell | Open Market | 5,746 | $204K | 5/14/2026 |
| Evan Lippman | ▲ Buy | Option Exercise | 74,008 | — | 5/14/2026 |
| Evan Lippman | ▼ Sell | Open Market | 35,912 | $1.3M | 5/14/2026 |
| Amir Weiss | ▼ Sell | Open Market | 10,679 | $384K | 5/6/2026 |
| Richard Daniell | ▼ Sell | Open Market | 30,000 | $1.1M | 5/5/2026 |
| Mark Sabag | ▼ Sell | Open Market | 144,180 | $5.0M | 5/1/2026 |
| Christine Fox | ▼ Sell | Open Market | 21,258 | $751K | 4/30/2026 |
| Mark Sabag | ▼ Sell | Open Market | 62,102 | $1.9M | 3/17/2026 |
| Mark Sabag | ▲ Buy | Option Exercise | 15,723 | — | 3/5/2026 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 19,916 | — | 3/5/2026 |
| Amir Weiss | ▲ Buy | Option Exercise | 3,537 | — | 3/5/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 42,452 | — | 3/5/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 20,025 | $634K | 3/5/2026 |
| Christine Fox | ▲ Buy | Option Exercise | 17,819 | — | 3/5/2026 |
| Richard Daniell | ▲ Buy | Option Exercise | 17,295 | — | 3/5/2026 |
| Richard Daniell | ▼ Sell | Open Market | 17,295 | $548K | 3/5/2026 |
| Placid Jover | ▲ Buy | Option Exercise | 14,150 | — | 3/5/2026 |
| Placid Jover | ▼ Sell | Open Market | 14,150 | $448K | 3/5/2026 |
| Christine Fox | ▼ Sell | Open Market | 7,924 | $251K | 3/5/2026 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 19,654 | — | 3/5/2026 |
| Eric A. Hughes | ▼ Sell | Open Market | 9,533 | $302K | 3/5/2026 |
| Savage Brian | ▲ Buy | Option Exercise | 3,580 | — | 3/5/2026 |
| Savage Brian | ▼ Sell | Open Market | 1,127 | $36K | 3/5/2026 |
| Matthew Shields | ▲ Buy | Option Exercise | 17,295 | — | 3/5/2026 |
| Matthew Shields | ▼ Sell | Open Market | 17,295 | $548K | 3/5/2026 |
| Mark Sabag | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2026 |
| Mark Sabag | ▲ Buy | Option Exercise | 18,601 | — | 3/4/2026 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 50,223 | — | 3/4/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 23,393 | $759K | 3/4/2026 |
| Richard Daniell | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2026 |
| Richard Daniell | ▼ Sell | Open Market | 33,512 | $1.1M | 3/4/2026 |
| Richard Daniell | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2026 |
| Richard Daniell | ▼ Sell | Open Market | 20,461 | $664K | 3/4/2026 |
| Richard Daniell | ▼ Sell | Open Market | 37,372 | $1.2M | 3/4/2026 |
| Eric A. Hughes | ▼ Sell | Open Market | 11,277 | $366K | 3/4/2026 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2026 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2026 |
| Christine Fox | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2026 |
| Christine Fox | ▼ Sell | Open Market | 9,098 | $295K | 3/4/2026 |
| Savage Brian | ▲ Buy | Option Exercise | 4,744 | — | 3/4/2026 |
| Savage Brian | ▼ Sell | Open Market | 1,489 | $48K | 3/4/2026 |
| Savage Brian | ▲ Buy | Option Exercise | 3,466 | — | 3/4/2026 |
| Savage Brian | ▼ Sell | Open Market | 1,186 | $39K | 3/4/2026 |
| Amir Weiss | ▲ Buy | Option Exercise | 10,679 | — | 3/4/2026 |
| Amir Weiss | ▲ Buy | Option Exercise | 5,650 | — | 3/4/2026 |
| Amir Weiss | ▲ Buy | Option Exercise | 5,179 | — | 3/3/2026 |
| Richard Daniell | ▲ Buy | Option Exercise | 62,250 | — | 3/3/2026 |
| Richard Daniell | ▼ Sell | Open Market | 62,250 | $2.0M | 3/3/2026 |
| Richard Daniell | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 |
| Richard Daniell | ▼ Sell | Open Market | 66,735 | $2.2M | 3/3/2026 |
| Mark Sabag | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2026 |
| Mark Sabag | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 |
| Savage Brian | ▲ Buy | Option Exercise | 3,461 | — | 3/3/2026 |
| Savage Brian | ▼ Sell | Open Market | 1,274 | $41K | 3/3/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 67,231 | — | 3/3/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 30,903 | $1.0M | 3/3/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 891,315 | — | 3/3/2026 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 49,800 | — | 3/3/2026 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2026 |
| Eric A. Hughes | ▼ Sell | Open Market | 12,077 | $391K | 3/3/2026 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 |
| Eric A. Hughes | ▼ Sell | Open Market | 68,685 | $2.2M | 3/3/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 412,032 | $13.3M | 3/3/2026 |
| Eliyahu Sharon Kalif | ▼ Sell | Open Market | 345,810 | $11.6M | 2/26/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 161,656 | — | 2/15/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 161,656 | $5.5M | 2/15/2026 |
| Richard D. Francis | ▲ Buy | Option Exercise | 620,110 | — | 2/15/2026 |
| Richard D. Francis | ▼ Sell | Open Market | 286,122 | $9.8M | 2/15/2026 |
| Amir Weiss | ▼ Sell | Open Market | 12,300 | $372K | 12/16/2025 |
| Roberto Mignone | ▼ Sell | Open Market | 77,400 | $2.3M | 12/16/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 118,724 | $2.2M | 12/9/2025 |
| Mark Sabag | ▼ Sell | Open Market | 118,724 | $3.4M | 12/9/2025 |
| Mark Sabag | ▼ Sell | Open Market | 98,168 | $2.8M | 12/9/2025 |
| Richard Daniell | ▼ Sell | Open Market | 115,468 | $3.3M | 12/9/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 100,457 | $1.9M | 12/9/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 15,011 | $255K | 12/9/2025 |
| Chen Lichtenstein | ▲ Buy | Option Exercise | 4,804 | — | 12/2/2025 |
| Roberto Mignone | ▼ Sell | Open Market | 50,000 | $1.3M | 11/26/2025 |
| Christine Fox | ▼ Sell | Open Market | 28,229 | $700K | 11/20/2025 |
| Christine Fox | ▲ Buy | Option Exercise | 63,492 | — | 11/20/2025 |
| Christine Fox | ▼ Sell | Open Market | 30,000 | $753K | 11/14/2025 |
| Roberto Mignone | ▼ Sell | Open Market | 200,000 | $4.8M | 11/6/2025 |
| Amir Weiss | ▼ Sell | Open Market | 12,300 | $301K | 11/6/2025 |
| McAvoy David R. | ▲ Buy | Open Market | 1,113 | $21K | 9/5/2025 |
| Placid Jover | ▼ Sell | Open Market | 6,053 | $92K | 8/1/2025 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 52,742 | — | 8/1/2025 |
| Eric A. Hughes | ▼ Sell | Open Market | 52,742 | $799K | 8/1/2025 |
| Placid Jover | ▲ Buy | Option Exercise | 12,827 | — | 8/1/2025 |
| Eliyahu Sharon Kalif | ▼ Sell | Open Market | 55,775 | $952K | 6/12/2025 |
| Rosemary A. Crane | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Roberto Mignone | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Sol J. Barer | ▲ Buy | Option Exercise | 17,158 | — | 6/6/2025 |
| Janet S. Vergis | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Tal Zvi Zaks | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Shalev Varda | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Ronit Satchi-Fainaro | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Perry Nisen | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Gerald M. Lieberman | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Amir Elstein | ▲ Buy | Option Exercise | 9,632 | — | 6/6/2025 |
| Matthew Shields | ▲ Buy | Option Exercise | 16,195 | — | 6/3/2025 |
| Matthew Shields | ▼ Sell | Open Market | 6,206 | $106K | 6/3/2025 |
| Mark Sabag | ▼ Sell | Open Market | 337,915 | $6.1M | 5/8/2025 |
| Amir Weiss | ▲ Buy | Option Exercise | 3,566 | — | 3/5/2025 |
| McAvoy David R. | ▼ Sell | Open Market | 1,677 | $27K | 3/5/2025 |
| Richard Daniell | ▼ Sell | Open Market | 48,385 | $769K | 3/5/2025 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 21,390 | — | 3/5/2025 |
| Richard Daniell | ▼ Sell | Open Market | 22,576 | $359K | 3/5/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2025 |
| Christine Fox | ▼ Sell | Open Market | 2,147 | $34K | 3/5/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 23,765 | — | 3/5/2025 |
| Eric A. Hughes | ▼ Sell | Open Market | 8,077 | $129K | 3/5/2025 |
| Richard Daniell | ▼ Sell | Open Market | 11,641 | $185K | 3/5/2025 |
| Richard Daniell | ▼ Sell | Open Market | 7,108 | $113K | 3/5/2025 |
| Richard Daniell | ▼ Sell | Open Market | 30,015 | $478K | 3/5/2025 |
| Richard D. Francis | ▼ Sell | Open Market | 8,259 | $131K | 3/5/2025 |
| Christine Fox | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2025 |
| Christine Fox | ▼ Sell | Open Market | 4,034 | $63K | 3/4/2025 |
| McAvoy David R. | ▼ Sell | Open Market | 3,150 | $50K | 3/4/2025 |
| McAvoy David R. | ▲ Buy | Option Exercise | 16,741 | — | 3/4/2025 |
| Amir Weiss | ▲ Buy | Option Exercise | 10,676 | — | 3/4/2025 |
| Amir Weiss | ▲ Buy | Option Exercise | 5,650 | — | 3/4/2025 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2025 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2025 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 183,169 | — | 3/4/2025 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2025 |
| Eric A. Hughes | ▼ Sell | Open Market | 15,174 | $239K | 3/4/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 18,601 | — | 3/4/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 183,169 | — | 3/4/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2025 |
| Richard D. Francis | ▼ Sell | Open Market | 6,450 | $100K | 3/4/2025 |
| Richard Daniell | ▼ Sell | Open Market | 21,870 | $344K | 3/4/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2025 |
| Richard Daniell | ▼ Sell | Open Market | 13,353 | $210K | 3/4/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 183,169 | — | 3/4/2025 |
| Richard Daniell | ▼ Sell | Open Market | 56,385 | $887K | 3/4/2025 |
| Richard D. Francis | ▲ Buy | Option Exercise | 50,223 | — | 3/4/2025 |
| Richard D. Francis | ▼ Sell | Open Market | 15,514 | $244K | 3/4/2025 |
| Richard Daniell | ▼ Sell | Open Market | 12,936 | $201K | 3/4/2025 |
| Eric A. Hughes | ▼ Sell | Open Market | 5,174 | $80K | 3/4/2025 |
| Richard D. Francis | ▼ Sell | Open Market | 24,892 | $403K | 3/3/2025 |
| Eliyahu Sharon Kalif | ▲ Buy | Option Exercise | 49,800 | — | 3/3/2025 |
| Amir Weiss | ▲ Buy | Option Exercise | 5,179 | — | 3/3/2025 |
| Mark Sabag | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2025 |
| Richard Daniell | ▲ Buy | Option Exercise | 62,250 | — | 3/3/2025 |
| Richard Daniell | ▼ Sell | Open Market | 49,314 | $798K | 3/3/2025 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2025 |
| Eric A. Hughes | ▼ Sell | Open Market | 19,726 | $319K | 3/3/2025 |
| Richard D. Francis | ▲ Buy | Option Exercise | 67,231 | — | 3/3/2025 |
| Eliyahu Sharon Kalif | ▼ Sell | Open Market | 55,750 | $903K | 2/28/2025 |
| Richard D. Francis | ▼ Sell | Open Market | 75,506 | $1.3M | 2/18/2025 |
| Richard D. Francis | ▲ Buy | Option Exercise | 161,655 | — | 2/15/2025 |
| Mark Sabag | ▼ Sell | Open Market | 177,626 | $2.9M | 2/12/2025 |
| Roberto Mignone | ▼ Sell | Open Market | 286,000 | $6.3M | 12/20/2024 |
| Christine Fox | ▲ Buy | Option Exercise | 63,492 | — | 11/20/2024 |
| Christine Fox | ▼ Sell | Open Market | 19,388 | $327K | 11/20/2024 |
| Shalev Varda | ▲ Buy | Option Exercise | 12,872 | — | 9/2/2024 |
| Richard Daniell | ▼ Sell | Open Market | 98,943 | $1.7M | 8/12/2024 |
| Grant Angus | ▲ Buy | Option Exercise | 12,913 | — | 8/9/2024 |
| Grant Angus | ▼ Sell | Open Market | 4,065 | $70K | 8/9/2024 |
| Eric A. Hughes | ▼ Sell | Open Market | 45,060 | $783K | 8/9/2024 |
| Eric A. Hughes | ▲ Buy | Option Exercise | 52,742 | — | 8/1/2024 |
| Eric A. Hughes | ▼ Sell | Open Market | 24,537 | $423K | 8/1/2024 |
| Roberto Mignone | ▼ Sell | Open Market | 519,000 | $8.8M | 6/18/2024 |
| Janet S. Vergis | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 |
| Gerald M. Lieberman | ▲ Buy | Option Exercise | 21,108 | — | 6/15/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.